ACA

NEUTRALM&A

Arcosa, Inc.

2026-08-19

Price

$145.25

-0.07%

This is the 2026-08-19 snapshot — the signals and analysis for ACA as of this single trading day.

View full ACA research hub →

Score9.0Priority

Signals6/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume0.9xvs 20d avg

Analysis

Arcosa's (ACA) exceptionally tight price action is completely driven by its pending $150-per-share all-cash acquisition by CRH plc. The ultra-low 2.7% realized volatility and technical signals like QUIET_STORM and BOLLINGER_SQUEEZE perfectly reflect a stock trading as a pure merger arbitrage vehicle rather than a directional equity. While the broader RISK_ON (RATES) macro regime is highly supportive of risk assets, ACA is fundamentally detached from macro beta and immune to market swings. The current price of $145.25 leaves a ~3.2% gross spread, offering a high-conviction, idiosyncratic yield play anchored to the deal's expected Q1 2027 close.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEMARKET LEADERPERFECT STACK

Key Takeaways

Actionable Thesis: ACA is a pure merger arbitrage opportunity offering a ~$4.75 gross spread to the $150 all-cash acquisition price from CRH.
Key Risk: Regulatory pushback, timeline extensions beyond Q1 2027, or failure to secure approval at the September 4th shareholder meeting.
What to Watch: Monitor the upcoming Special Meeting of Stockholders on September 4, 2026, alongside standard antitrust regulatory filings.

← Back to 2026-08-19 View Full ACA History →Yahoo Finance &nearr;